Becton, Dickinson and Company
As of Oct 22, 2026, Becton, Dickinson is in Stage 2, the uptrend phase, now in week 11 (since Aug 10, 2026). It closed at $200.42, at its 52-week high and above its 200-day average, which is rising.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researche… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 18 in Medical Instruments & Supplies · #1 of 272 in Health Care
Is BDX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
BDX among Medical Instruments & Supplies6th of 51 by relative strength
All 51 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | PLSE | Stage 2 · wk 34 | 98 | +1.3% |
| 2 | PDEX | Stage 2 · wk 36 | 97 | −13.3% |
| 3 | HBIO | Stage 2 · wk 11 | 95 | +3.6% |
| 4 | ATRC | Stage 2 · wk 10 | 89 | −1.1% |
| 5 | WST | Stage 2 · wk 24 | 82 | +4.8% |
| 6 | BDX | Stage 2 · wk 11 | 81 | +9.8% |
| 7 | ICUI | Stage 3 · wk 1 | 81 | +3.1% |
| 8 | OSUR | Stage 3 · wk 8 | 75 | −4.8% |
Becton, Dickinson: quick answers
What stage is Becton, Dickinson in?
As of Oct 22, 2026, Becton, Dickinson (BDX) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 10, 2026 and is in week 11. What the four stages mean
Is Becton, Dickinson in an uptrend?
Yes. Becton, Dickinson is in a Stage 2 uptrend. It trades 22.7% above its 200-day average, which is rising.
How far is Becton, Dickinson from its 52-week high?
Becton, Dickinson closed at $200.42 on Oct 22, 2026, at its 52-week high. Its 52-week low is $135.29.
How has Becton, Dickinson performed over the past year?
As of Oct 22, 2026, Becton, Dickinson is up 38.2% over the past year and up 33.3% so far in 2026.
Which sector and industry is Becton, Dickinson in?
Becton, Dickinson is in the Medical Instruments & Supplies industry, part of the Health Care sector.
About this companyHealth Care· Medical Instruments & Supplies
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.